Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients

NCT03877809 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Beta-Thalassemia

Interventions

DRUG: Sirolimus 0.5 mg

Sponsor

Rare Partners srl Impresa Sociale

Collaborators

[object Object]